Product Information
| Molecular Weight | 275.3 g/mol |
| Purity | >98% |
| Molecular Formula | C16H21NO3 |
| CAS | 61413-54-5 |
| Solubility | Soluble in DMSO at 25 mg/mL or ethanol at 25 mg/mL. |
The small-molecule Rolipram is an inhibitor of phosphodiesterase 4 (PDE4), which catalyzes the hydrolysis of cyclic-AMP (cAMP) to regulate cellular responses to a number of extracellular signals. Rolipram inhibits multiple isozymes of PDE4, including PDE4A (IC50 = 3 nM), PDE4B (IC50 = 130 nM), and PDE4D (IC50 = 240 nM). Treatment of myeloid cells with Rolipram resulted in phosphorylation of cAMP-response element-binding protein (CREB) and implied the presence of both high (PDE4A4) and low affinity (PDE4B, PDE4D) components (1). Rolipram and other phosphodiesterase inhibitors were seen as having potential therapeutic benefits in preclinical models of psychiatric and neurologic diseases. Unfortunately, severe dose-limiting side effects (e.g., nausea, vomiting) limited the clinical application of PDE inhibitors (2). Still, Rolipram treatment in a mouse model of intracerebral hemorrhage demonstrated some neuroprotective benefits through activation of the cAMP/AMPK/SIRT1 pathway (3). Rolipram treatment of fibroblasts from ligamentum flavum hypertrophy patients inhibited PDE4A and PDE4B activity, blocked TGF-β1 by restoring p-ERK1/2 expression, and inhibited expression of fibrosis-related proteins (4).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
| Cat. # | Size | Qty. | Price |
|---|---|---|---|
| 57192S | 10 mg |
|
